|
1
|
Frasure-Smith N, Lespérance F, Irwin MR,
Talajic M and Pollock BG: The relationships among heart rate
variability, inflammatory markers and depression in coronary heart
disease patients. Brain Behav Immun. 23:1140–1147. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thombs BD, Bass EB, Ford DE, Stewart KJ,
Tsilidis KK, Patel U, Fauerbach JA, Bush DE and Ziegelstein RC:
Prevalence of depression in survivors of acute myocardial
infarction. J Gen Intern Med. 21:30–38. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mathews MJ, Mathews EH and Liebenberg L:
The mechanisms by which antidepressants may reduce coronary heart
disease risk. BMC Cardiovasc Disord. 15:822015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nemeroff CB and Goldschmidt-Clermont PJ:
Heartache and heartbreak-the link between depression and
cardiovascular disease. Nat Rev Cardiol. 9:526–539. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nelson JC, Kennedy JS, Pollock BG,
Laghrissi-Thode F, Narayan M, Nobler MS, Robin DW, Gergel I,
McCafferty J and Roose S: Treatment of major depression with
nortriptyline and paroxetine in patients with ischemic heart
disease. Am J Psychiatry. 156:1024–1028. 1999.PubMed/NCBI
|
|
6
|
Sirtori CR and Fumagalli R:
LDL-cholesterol lowering or HDL-cholesterol raising for
cardiovascular prevention. A lesson from cholesterol turnover
studies and others. Atherosclerosis. 186:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kobayashi J, Maruyama T, Masuda M and
Shinomiya M: Effect of atorvastatin treatment on lipoprotein lipase
mass in the pre-heparin plasma in Japanese hyperlipidemic subjects.
Clin Chim Acta. 314:261–264. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eshtehardi P, McDaniel MC, Dhawan SS,
Binongo JN, Krishnan SK, Golub L, Corban MT, Raggi P, Quyyumi AA
and Samady H: Effect of intensive atorvastatin therapy on coronary
atherosclerosis progression, composition, arterial remodeling, and
microvascular function. J Invasive Cardiol. 24:522–529.
2012.PubMed/NCBI
|
|
9
|
Baumeister H, Hutter N and Bengel J:
Psychological and pharmacological interventions for depression in
patients with coronary artery disease. Cochrane Database Syst Rev.
CD0080122011.PubMed/NCBI
|
|
10
|
Roose SP: Treatment of depression in
patients with heart disease. Biol Psychiatry. 54:262–268. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Roose SP and Miyazaki M: Pharmacological
treatment of depression in patients with heart disease. Psychosom
Med. 67(Suppl 1): S54–S57. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanchez C, Reines EH and Montgomery SA: A
comparative review of escitalopram, paroxetine, and sertaline: Are
they all alike? Int Clin Psychopharmacol. 29:185–196. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vaswani M, Linda FK and Ramesh S: Role of
selective serotonin reuptake inhibitors in psychiatric disorders: A
comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry.
27:85–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bolego C, Baetta R, Bellosta S, Corsini A
and Paoletti R: Safety considerations for statins. Curr Opin
Lipidol. 13:637–644. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Andrade C: Selective serotonin reuptake
inhibitor drug interactions in patients receiving statins. J Clin
Psychiatry. 75:e95–e99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jornil J, Jensen KG, Larsen F and Linnet
K: Identification of cytochrome P450 isoforms involved in the
metabolism of paroxetine and estimation of their importance for
human paroxetine metabolism using a population-based simulator.
Drug Metab Dispos. 38:376–385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bhattacharyya S, Sinha K and Sil PC:
Cytochrome P450s: Mechanisms and biological implications in drug
metabolism and its interaction with oxidative stress. Curr Drug
Metab. 15:719–742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deavall DG, Martin EA, Horner JM and
Roberts R: Drug-induced oxidative stress and toxicity. J Toxicol.
2012:6454602012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cunha-Oliveira T, Rego AC and Oliveira CR:
Oxidative stress and drugs of abuse: An update. Mini-Rev Org Chem.
10:000. 2013. View Article : Google Scholar
|
|
20
|
Guengerich FP: Cytochrome P450s and other
enzymes in drug metabolism and toxicity. AAPS J. 8:E101–E111. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lins RL, Matthys KE, Verpooten GA, Peeters
PC, Dratwa M, Stolear JC and Lameire NH: Pharmacokinetics of
atorvastatin and its metabolites after single and multiple dosing
in hypercholesterolaemic haemodialysis patients. Nephrol Dial
Transplant. 18:967–976. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Fang P, Mai J, Choi ET, Wang H and
Yang XF: Targeting mitochondrial reactive oxygen species as novel
therapy for inflammatory diseases and cancers. J Hematol Oncol.
6:192013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Paglia DE and Valentine WN: Studies on the
quantitative and qualitative characterization of erythrocyte
glutathione peroxidase. J Lab Clin Med. 70:158–169. 1967.PubMed/NCBI
|
|
24
|
Herbet M, Gawrońska-Grzywacz M and
Jagiełło-Wójtowicz E: Evaluation of selected biochemical parameters
of oxidative stress in rats pretreated with rosuvastatin and
fluoxetine. Acta Pol Pharm. 72:261–265. 2015.PubMed/NCBI
|
|
25
|
Herbet M, Izdebska M, Piątkowska-Chmiel I,
Poleszak E and Jagiełło-Wójtowicz E: Estimation of oxidative stress
parameters in rats after simultaneous administration of
rosuvastatin with antidepressants. Pharmacol Rep. 68:172–176. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Almeida J, Duarte JO, Oliveira LA and
Crestani CC: Effects of nitric oxide synthesis inhibitor or
fluoxetine treatment on depression-like state and cardiovascular
changes induced by chronic variable stress in rats. Stress.
18:462–474. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park BK, Laverty H, Srivastava A, Antoine
DJ, Naisbitt D and Williams DP: Drug bioactivation and protein
adduct formation in the pathogenesis of drug-induced toxicity. Chem
Biol Interact. 192:30–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Webb HM, Regan S, Antoine DJ, Lane N,
Walsh RJ, Srivastava A, Starkey-Lewis P, Benson C, Williams DP,
Laverty H, et al: Drug Bioactivation and Oxidative
StressEncyclopedia of Drug Metabolism and Interactions. Lyubimov
AV: John Wiley & Sons; New York: pp. 1–31. 2012
|
|
29
|
Chang JC, van der Hoeven LH and Haddox CH:
Glutathione reductase in the red blood cells. Ann Clin Lab Sci.
8:23–29. 1978.PubMed/NCBI
|
|
30
|
Koksal M, Eren MA, Turan MN and Sabuncu T:
The effects of atorvastatin and rosuvastatin on oxidative stress in
diabetic patients. Eur J Intern Med. 22:249–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bloom HL, Shukrullah I, Veledar E, Gutmann
R, London B and Dudley SC: Statins decrease oxidative stress and
ICD therapies. Cardiol Res Pract. 2010:2538032010.PubMed/NCBI
|
|
32
|
Nagila A, Permpongpaiboon T, Tantrarongroj
S, Porapakkham P, Chinwattana K, Deakin S and Porntadavity S:
Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status.
Pharmacol Rep. 61:892–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cangemi R, Loffredo L, Carnevale R, Perri
L, Patrizi MP, Sanguigni V, Pignatelli P and Violi F: Early
decrease of oxidative stress by atorvastatin in
hypercholesterolaemic patients: Effect on circulating vitamin E.
Eur Heart J. 29:54–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Abdel-Salam OME, Morsy SM Youssef and
Sleem AA: The effect of different antidepressant drugs on oxidative
stress after lipopolysaccharide administration in mice. EXCLI J.
10:290–302. 2011.
|
|
35
|
Zafir A and Banu N: Antioxidant potential
of fluoxetine in comparison to Curcuma longa in restraint-stressed
rats. Eur J Pharmacol. 572:23–31. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Novío S, Núñez MJ, Amigo G and
Freire-Garabal M: Effects of fluoxetine on the oxidative status of
peripheral blood leucocytes of restraint-stressed mice. Basic Clin
Pharmacol Toxicol. 109:365–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qiu HM, Yang JX, Wu XH, Li N, Liu D, Wang
LJ, Qin LJ and Zhou QX: Antidepressive effect of paroxetine in a
rat model: Upregulating expression of serotonin and norepinephrine
transporter. Neuroreport. 24:520–525. 2013. View Article : Google Scholar : PubMed/NCBI
|
